Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
Từ khóa
trừu tượng
Sự miêu tả
Schizophrenia is a major psychiatric disorder with a chronic and debilitating course. It is the archetypal psychotic disorder with a prevalence of about 1% worldwide. The treatment of this psychotic disorder has evolved over the years after the discovery of Chlorpromazine. Despite the availability of several treatment options in practice, research into the possibility of creating a drug breakthrough continues.
Sorghum bicolor, a naturally growing plant rich in several phytochemical including proanthocyanidins, anthocyanidins, apigenin, proapigeninidin, apigeninidin, luteolin, naringenins, flavonoids, and polyphenols (Omogbiya et al 2012) and prepared as a capsule called Jobelyn. This plant has been found to be of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons. The anti-inflammatory and haematocrit boosting properties have been well documented and utilized though the precise mechanism of action is still not entirely known (Benson et al. 2013). Its usefulness in neuropsychiatric conditions has recently been explored albeit through animal studies.
In animals, Jobelyn has been suggested to have anti-amnestic property which has been suggested to be related to its antioxidant activity (Umukoro et al. 2013a). Other studies also suggested that Jobelyn has an anti-aggressive effect (Umukoro et al. 2012) and antidepressant like property probably related to its stimulation of serotonergic pathways (Umukoro et al. 2013b). Jobelyn has also been suggested to exhibit anti-psychotic-like activity with the benefit of lacking extra-pyramidal side effect risks and therefore being postulated to be of possible benefit in the symptomatic relief of psychosis (Omogbiya et al. 2012).
There is however limited information in terms of the suggested neuropsychiatric conditions especially in humans despite the recognized safety profile consequent upon its use as haematocrit boosting agent. This study therefore aims at exploring the usefulness of Jobelyn in the treatment of patients with Schizophrenia as an adjunct to standard treatment.
ngày
| Xác minh lần cuối: | 01/31/2017 |
| Đệ trình đầu tiên: | 09/10/2014 |
| Đăng ký ước tính đã được gửi: | 09/10/2014 |
| Đăng lần đầu: | 09/14/2014 |
| Cập nhật lần cuối được gửi: | 02/13/2017 |
| Cập nhật lần cuối đã đăng: | 02/15/2017 |
| Ngày bắt đầu nghiên cứu thực tế: | 05/31/2017 |
| Ngày hoàn thành chính ước tính: | 11/30/2017 |
| Ngày hoàn thành nghiên cứu ước tính: | 11/30/2017 |
Tình trạng hoặc bệnh tật
Can thiệp / điều trị
Dietary Supplement: Jobelyn + Haloperidol
Drug: Haloperidol + Placebo
Giai đoạn
Nhóm cánh tay
| Cánh tay | Can thiệp / điều trị |
|---|---|
| Experimental: Jobelyn + Haloperidol Combination of the conventional drugs and Jobelyn | Dietary Supplement: Jobelyn + Haloperidol Jobelyn is a dietary supplement made from Sorghum bicolor |
| Active Comparator: Haloperidol + Placebo Combination of the conventional drug + Placebo | Drug: Haloperidol + Placebo Conventional drug normally used for psychotic problems |
Đủ tiêu chuẩn
| Giới tính đủ điều kiện để nghiên cứu | All |
| Chấp nhận tình nguyện viên lành mạnh | Đúng |
| Tiêu chí | Inclusion Criteria: Participants will be adults with current diagnosis of schizophrenia (meeting the ICD-10 criteria). - Adults who are above 18 years of age and gave informed consent - Currently meet the ICD-10 diagnosis of Schizophrenia and confirmed with MINI- PLUS - Antipsychotic naive before recruitment into study or defaulted from treatment for at least 6 months 'prior to contact with study - Not on Jobelyn or Megafit currently or in the past 6months prior to contact with study Exclusion Criteria: - Having another current ICD-l0 diagnosis or a seizure disorder - Serious or chronic physical illness - Known severe drug allergies or hypersensitivity to Jobelyn, Megafit or Haloperidol |
Kết quả
Các biện pháp kết quả chính
1. The primary outcome will be the changes in psychotic symptoms [8 Weeks]
Các biện pháp kết quả thứ cấp
1. Patient's general health and social functioning [8 Weeks]
Các biện pháp kết quả khác
1. Side effects [8 Weeks]
